Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
About this trial
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
Eligibility criteria
Qualifiers
Fully understand the study and voluntarily sign the informed consent form;
Age ≥18 years old;
Pathologically (including histologically or cytologically) confirmed as peritoneal mesothelioma;
ECOG performance status of 0-1;
Disqualifiers
Unable to adhere to the study protocol or procedures;
Vaccination with live vaccines within 4 weeks before enrollment or expected during the study period;
Other malignancies within the past 5 years, except for cured basal or squamous cell skin cancer, thyroid papillary carcinoma, or in situ cervical cancer;
Active autoimmune diseases or a history of autoimmune diseases within 4 weeks prior to enrollment;
Trial design
Treatments tested in this trial
- Sintilimab, Bevacizumab , Pemetrexed , Cisplatin
Treatment groups
28 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov